1. Home
  2. ZKH vs PRTA Comparison

ZKH vs PRTA Comparison

Compare ZKH & PRTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

ZKH

ZKH Group Limited

N/A

Current Price

$3.35

Market Cap

571.2M

Sector

N/A

ML Signal

N/A

Logo Prothena Corporation plc

PRTA

Prothena Corporation plc

HOLD

Current Price

$8.61

Market Cap

501.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ZKH
PRTA
Founded
1998
2012
Country
China
Ireland
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
571.2M
501.2M
IPO Year
2022
2013

Fundamental Metrics

Financial Performance
Metric
ZKH
PRTA
Price
$3.35
$8.61
Analyst Decision
Buy
Analyst Count
0
9
Target Price
N/A
$19.00
AVG Volume (30 Days)
22.8K
461.7K
Earning Date
01-01-0001
05-20-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$814,000.00
Revenue This Year
$2.58
$1,111.38
Revenue Next Year
$10.62
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$2.50
$4.32
52 Week High
$3.90
$13.71

Technical Indicators

Market Signals
Indicator
ZKH
PRTA
Relative Strength Index (RSI) 43.07 40.05
Support Level $3.12 $8.13
Resistance Level $3.48 $8.78
Average True Range (ATR) 0.09 0.47
MACD -0.00 -0.07
Stochastic Oscillator 32.56 9.22

Price Performance

Historical Comparison
ZKH
PRTA

About ZKH ZKH Group Limited

ZKH Group Ltd engages in providing MRO procurement service platform in China. It provides one-stop MRO procurement and management services for its customers, and offers digital and fulfillment solutions for participants along the industry value chain. It offers a broad range of MRO product offerings covering all MRO product lines on its platform, including spare parts, chemicals, manufacturing parts, general consumables, and office supplies. All of the Group's revenues are derived from the PRC.

About PRTA Prothena Corporation plc

Prothena Corp PLC is a late-stage clinical biotechnology company that focuses on protein dysregulation and a pipeline of investigational therapeutics with the potential to change the course of devastating neurodegenerative and rare and peripheral amyloid diseases. Prothena is developing and applying its proprietary CYTOPE technology to target a broad spectrum of intracellular disease pathways in the brain and periphery. The company's pipeline includes both wholly-owned and partnered programs like Prasinezumab, Coramitug (PRX004), BMS-986446 (PRX005), PRX019, TDP-43 CYTOPE, and PRX012-TfR, being developed for the potential treatment of Parkinson's disease, ATTR amyloidosis with cardiomyopathy, Alzheimer's disease, Amyotrophic lateral sclerosis (ALS), and other neurodegenerative diseases.

Share on Social Networks: